Constraint-Based Therapy to Improve Motor Function in Children With Cerebral Palsy

Randomized Controlled Trial of Pediatric CI Therapy

Pediatric Constraint-Induced (CI) Movement therapy is a rehabilitation program designed to improve motor function in children with partial paralysis. Children with cerebral palsy may have one arm that has significantly greater function (good arm) than the other (bad arm). Restricting the use of the good arm may improve the use of the bad arm. In pediatric CI therapy, the good arm is put in a sling to force increased use of the bad arm. The bad arm is also trained each day for several weeks. This study will test the ability of pediatric CI therapy to improve motor function in children with cerebral palsy.

Study Overview

• Status: Unknown
• Conditions: Cerebral Palsy; Motor Deficits
• Intervention / Treatment: Behavioral: Pediatric Constraint-Induced Movement therapy; Behavioral: Conventional pediatric motor rehabilitation therapy

Detailed Description

Cerebral palsy afflicts at least two in 1,000 children in the United States and approximately 2,000,000 children worldwide. Behavioral techniques that impact the plasticity of the nervous system need to be incorporated into practical, evidence-based therapeutic interventions for this condition.

CI therapy was derived from basic research with animal and human subjects. Randomized, controlled studies indicate that it can substantially reduce the motor deficit of adult patients with mild to moderately severe chronic strokes and can increase their independence over a period of years. CI therapy involves motor restriction of the less affected upper extremity for a period of 2 to 3 weeks while concurrently training the more affected upper limb. This gives rise to concentrated, repetitive use of the more affected extremity. In adults, CI therapy has lead to a large increase in use-dependent cortical reorganization involving the recruitment of substantial new regions of the brain in the innervation of more affected extremity movement.

The study will evaluate CI therapy in a pediatric population. The study will test whether pediatric CI therapy can promote new and improved motor behavior in young children with hemiparesis associated with cerebral palsy. Pediatric CI therapy involves total restraint of the unaffected upper extremity with simultaneous repetitive use of the affected extremity for 6 hours/day for 21 consecutive days.

Fifty-two children ages 2 to 6 years old with hemiparetic cerebral palsy will be randomly assigned to either the pediatric CI therapy group or to a control group. The control group will receive standard rehabilitation therapy. All children will have a complete medical evaluation with emphasis on motor function prior to treatment initiation. Children will undergo follow-up testing at 1, 6, and 12 months post-treatment. The primary study assessment tools are the Pediatric Developmental Motor Scales - II (PDMS-II), DASI - II, Bayley Developmental Skills Test, Pediatric Motor Activity Log (PMAL), Child Arm Use Test (CAUT), and Emerging Behavior Scale (EBS).

• Study Type: Interventional
• Enrollment: 52
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Edward Taub, PhD; Phone Number: 205-934-2471; Email: etaub@uab.edu

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • Recruiting
      • University of Alabama at Birmingham
      • Contact: Edward Taub, PhD; Phone Number: 205-934-2471; Email: etaub@uab.edu
      • Principal Investigator: Edward Taub, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years to 6 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria

• Clinical diagnosis of hemiparetic cerebral palsy consistent with criteria in Swaiman and Russman (1999) and Badawi et al. (1998)
• Recommended for participation in pediatric rehabilitation and/or early intervention
• Lives within 50 miles of the Civitan Center at University of Alabama at Birmingham or the family is willing to temporarily relocate to the Birmingham area for treatment

Exclusion Criteria

• Profound bilateral hearing loss with the use of hearing aids
• Severe visual impairment
• Serious seizure disorder or uncontrolled seizures
• Genetic and syndromic conditions historically excluded for CP registries
• Familial Spastic Paraplegia
• Ataxic Cerebral Palsy
• Diagnosis of Pervasive Developmental Disability or autism
• Serious or recurring medical complications
• Scheduled for surgery within 12 months of study entry

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: Single

Collaborators and Investigators

• Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Investigators: Principal Investigator: Edward Taub, PhD, University of Alabama at Birmingham

Study record dates

Study Major Dates

• Study Start: September 1, 2002
• Primary Completion: December 7, 2022
• Study Completion: September 1, 2006

Study Registration Dates

• First Submitted: May 21, 2003
• First Submitted That Met QC Criteria: May 21, 2003
• First Posted (Estimate): May 22, 2003

Study Record Updates

• Last Update Posted (Estimate): June 24, 2005
• Last Update Submitted That Met QC Criteria: June 23, 2005
• Last Verified: April 1, 2003

More Information

Terms related to this study

• Keywords: Training; Upper extremity; Cerebral palsy; Hemiparesis; Pediatric CI therapy; Limb restraint
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Brain Damage, Chronic; Cerebral Palsy
• Other Study ID Numbers: R01HD040692 (U.S. NIH Grant/Contract)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No